CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($1.58), $0.37 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $7.1 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.